Feed / Theme
Confirmed

Industrial Automation & Services

25 names are moving together; 72% are participating in the current session.

Co-movement

Observed intraday paths are not available for this group yet.

Members

TICKERCompanySectorTodayObserved activity
AAUCAllied Gold CorporationBasic Materials+1.4%Group member
BKSYBlackSky Technology Inc.Industrials-1.9%Group member
KEPKorea Electric Power CorporatioUtilities+3.3%Group member
SUNCSunocoCorp LLCEnergy+0.2%Group member
LEALear CorporationConsumer Cyclical+0.9%Group member
DNTHDianthus Therapeutics, Inc.Healthcare-2.5%Group member
FRMIFermi Inc.Real Estate-10.1%Group member
MUFGMitsubishi UFJ Financial Group,Financial Services+1.9%Group member
ROKRockwell Automation, Inc.Industrials+1.0%Group member
NOVTNovanta Inc.Technology+3.3%Group member
BEPBrookfield Renewable Partners LUtilities-1.7%Group member
BLBDBlue Bird CorporationIndustrials-1.1%Group member
EMREmerson Electric CompanyIndustrials+0.7%Group member
RYAMRayonier Advanced Materials IncBasic Materials+3.8%Group member
PRLBProto Labs, Inc.Industrials-1.5%Group member
NMRNomura Holdings IncFinancial Services+1.2%Group member
PUKPrudential Public Limited CompaFinancial Services+1.3%Group member
HTHTH World Group LimitedConsumer Cyclical+0.4%Group member
HOVRNew Horizon Aircraft Ltd.Industrials+0.0%Group member
SMFGSumitomo Mitsui Financial GroupFinancial Services+0.9%Group member
DCHDauch CorporationConsumer Cyclical+0.1%Group member
VSATViaSat, Inc.Technology+4.4%Group member
VSTVistra Corp.Utilities+0.5%Group member
APHAmphenol CorporationTechnology-1.9%Group member

Why we believe this

Cohort

25 names

Participation

72% this session

Observed history

1 daily builds

Filing coverage

17/25 members

credit / rates affecting interest expense

The increase was primarily due to non-cash interest expense associated with the liability related to the sale of future royalties and the Credit Facility, partially offset by higher income from increased investment yields.

ARWR 10-K

product pipeline / R&D affecting expense

The increase in net income attributable to Arrowhead Pharmaceuticals, Inc. for the three months ended December 31, 2025 compared to the same period of 2024 was primarily due to an increase in revenue from the Sarepta Collaboration Agreement, partially offset by higher research and development expenses, associated with the expansion of the Company's pipeline and progression through clinical trial phases.

ARWR 10-Q

demand / volume affecting revenue

Net sales to the automotive market increased approximately $168.3, reflecting strength in demand from power management, infotainment communications, safety and security systems and antenna and related assemblies, along with contributions from acquisitions, partially offset by moderations in electric and hybrid drive train platforms.

APH 10-K

Cross-asset confirmation is still fragile, so spillover can stall before it becomes durable.

Connected, outside the group

No high-confidence filing-linked non-members are available for this group yet.

History

Historical cohort observations are not available yet.